uMotif – the patient-first data capture and decentralized clinical trials platform – announces $25.5m of new investment from a fund managed by Athyrium Capital Management
LONDON and NEW YORK, May 25, 2022-- uMotif today announced a
new investment of $25.5m from a fund managed by Athyrium Capital
Management, LP, the New York-based investment firm. The new funding will
support continued scale up of uMotif's unique patient-first software
platform for clinical research.
More info >> |